Could Existing Drugs Become the Next Breakthrough Treatments? The Opportunity in Drug Repurposing

Drug repurposing is creating another route for pharmaceutical innovation. Instead of discovering an entirely new molecule, researchers investigate whether an existing approved or investigational drug could treat a different disease or patient population.

This approach can make use of established pharmacological information, safety data and previous clinical research. It may reduce some early development uncertainties, although a new therapeutic indication still requires appropriate evidence of safety, efficacy and regulatory approval.

For pharmaceutical companies, biotechnology developers and investors, drug repurposing creates opportunities across clinical research, AI-based drug discovery, licensing, formulation development and evidence generation.

Industry Snapshot: U.S. Agencies Are Increasing Their Focus on Drug Repurposing

Recent developments from U.S. health agencies indicate growing institutional interest in identifying new uses for existing medicines.

FDA launches a drug repurposing initiative

On May 11, 2026, the U.S. Food and Drug Administration announced an initiative to identify potential new uses for FDA-approved drugs addressing unmet medical needs.

The agency specifically highlighted chronic and rare diseases, including metabolic disorders, neurodegenerative conditions, women's and men's health conditions, and substance use disorders.

The FDA is seeking information on drug candidates with existing clinical evidence, promising preliminary research and preclinical findings, including those identified through artificial intelligence and machine learning. <Cite refs={["turn169032search0","turn169032search2"]}/>

NIH introduces the ReGen Drugs programme

The National Institutes of Health, through its National Center for Advancing Translational Sciences (NCATS), has developed the Repurposing Generic (ReGen) Drugs programme.

In November 2026, NIH announced the ReGen Drugs Evidence Package Challenge, with $4 million in total prizes. The initiative seeks evidence-supported opportunities to repurpose generic drugs for high-cost conditions.

Priority areas include Alzheimer's disease, cancer, chronic kidney disease, cardiovascular diseases, diabetes, neurological conditions, osteoarthritis and substance use disorders. <Cite refs={["turn169032search3"]}/>

FDA Project Renewal updates older oncology drug information

Project Renewal, led by the FDA Oncology Center of Excellence, evaluates publicly available scientific evidence to update prescribing information for selected older oncology medicines.

The initiative can address outdated information, including indications, dosage and administration, where supported by appropriate evidence. It provides an established example of how accumulated clinical research can support improvements in the use and labelling of existing drugs. <Cite refs={["turn169032search1","turn169032search4"]}/>

Key Segments of Drug Repurposing

1. Oncology and Rare Diseases

Cancer and rare diseases represent important areas for drug repositioning because some patient populations have limited treatment options.

Researchers are investigating whether existing compounds can affect tumour growth, disease pathways or treatment resistance in new patient populations.

For rare diseases, repurposing may offer a way to investigate existing medicines where developing a completely new molecule would be commercially challenging.

2. Neurological and Neurodegenerative Disorders

Alzheimer's disease, Parkinson's disease, multiple sclerosis and other neurological conditions have complex biological mechanisms.

Researchers are examining whether medicines originally developed for other conditions can influence inflammation, neuroprotection, cellular signalling or disease progression.

The main challenge is demonstrating meaningful clinical benefit rather than relying only on laboratory findings.

3. Metabolic and Inflammatory Diseases

Existing medicines may have biological effects beyond their original approved indications.

Researchers are exploring potential new applications in metabolic disorders, chronic inflammation, cardiovascular conditions and other diseases involving overlapping biological pathways.

These programmes can benefit from existing pharmacological and clinical information, but dose requirements and safety profiles must be reassessed for the new patient population.

4. Generic Drug Repositioning

Generic medicines are an important focus because their established manufacturing processes and existing clinical exposure can offer development advantages.

However, low commercial incentives can discourage companies from funding new indication studies when generic competition limits the potential return on investment.

The NIH ReGen programme directly addresses this challenge by encouraging evidence packages for generic drug-disease combinations with potential public health and healthcare cost benefits.

Organizations and Companies Advancing Drug Repurposing

The drug repurposing ecosystem includes government research agencies, biotechnology companies, academic institutions and pharmaceutical developers.

NIH and NCATS: Building Evidence for Generic Drug Repurposing

NCATS focuses on accelerating the translation of scientific discoveries into treatments.

Its ReGen Drugs programme aims to identify promising generic drug-disease combinations, develop supporting evidence and improve the possibility of clinical adoption.

The programme is particularly relevant to conditions with substantial healthcare costs, where an affordable repurposed generic medicine could offer significant economic value if clinical effectiveness is demonstrated.

BARDA ReDIRECT: Repurposing Medicines for Medical Countermeasures

BARDA's Division of Research, Innovation, and Ventures (DRIVe) established ReDIRECT to investigate commonly available therapeutics for use against chemical threats.

MediciNova's MN-166, also known as ibudilast, became the first compound to receive development support through the programme. It was investigated as a potential treatment for chlorine-induced acute lung injury.

This example illustrates how a medicine with an established clinical development history can be evaluated for a different application. The programme focuses on medical countermeasures, rather than general-purpose treatment repositioning. <Cite refs={["turn869116search3","turn869116search7"]}/>

FDA Project Renewal: Generating Value From Existing Clinical Evidence

Project Renewal uses expert review of published scientific evidence to evaluate whether prescribing information for selected older oncology medicines should be updated.

Its work demonstrates the importance of evidence generation and regulatory engagement in drug repurposing. A medicine's historical clinical use can provide valuable information, but any proposed new indication must meet the relevant regulatory evidence requirements.

Where Are the Market Gaps?

1. Limited Commercial Incentives

Generic medicines often face price competition and limited exclusivity. Pharmaceutical companies may hesitate to finance expensive clinical trials when competitors can benefit from the same new evidence.

2. Insufficient Clinical Evidence

A promising laboratory result or retrospective study does not establish that a medicine will work in patients with a different condition.

Developers need appropriately designed clinical trials, validated endpoints, suitable patient populations and reliable safety assessments.

3. Regulatory and Intellectual Property Challenges

A new indication may require additional clinical evidence, regulatory submissions and changes to prescribing information.

Patent protection can also be difficult when the original molecule and formulation are already widely available. Companies must assess new-use patents, formulation patents, regulatory exclusivity and licensing rights.

4. Funding and Trial Design Constraints

Repurposing programmes may struggle to secure funding for prospective trials, particularly when the candidate is an inexpensive generic medicine.

Public-private partnerships, government research programmes and academic collaborations can help address this financing gap.

5. Fragmented Research and Data

Evidence about potential new drug uses may be distributed across clinical publications, trial registries, observational datasets, patents and preclinical studies.

Without structured analysis, promising drug-disease relationships can remain difficult to identify and prioritize.

Business Opportunities in Drug Repurposing

1. AI-Powered Drug and Disease Matching

AI and machine learning can analyse molecular interactions, gene-expression data, disease pathways and published research to identify potential new drug applications.

Opportunity: Develop computational platforms that connect existing compounds with disease targets and rank candidates based on biological plausibility, available evidence and development feasibility.

2. Clinical Research and Evidence Generation

Potential drug-disease combinations need further validation through clinical studies, observational research and real-world evidence.

Opportunity: Build partnerships among pharmaceutical companies, CROs, academic institutions and research hospitals to generate evidence for promising candidates.

3. New Indication Development and Licensing

Companies with established molecules may explore additional therapeutic indications through licensing and co-development agreements.

Opportunity: Identify molecules with promising evidence, assess intellectual property protection and connect asset owners with pharmaceutical partners that have relevant clinical and commercialization capabilities.

4. Repurposing Platforms for Rare and Neglected Diseases

Rare and neglected conditions often face limited commercial investment despite substantial unmet medical needs.

Opportunity: Develop focused drug-repositioning programmes that combine disease biology, existing clinical evidence and patient population analysis to prioritize affordable therapeutic candidates.

5. Generic Drug Development Partnerships

The NIH ReGen initiative highlights opportunities to generate evidence for generic medicines with potential applications in high-cost conditions.

Opportunity: Identify generic manufacturers, research organizations and funding partners interested in supporting clinical validation and potential label updates.

What Should Pharmaceutical Leaders and Investors Track?

Drug repurposing decisions require a structured assessment of scientific, clinical, regulatory and commercial factors.

A promising repurposing candidate should not be evaluated only by the number of publications or proposed indications. The strength of clinical evidence, feasibility of further development and potential commercial incentives are equally important.

How Towards Healthcare Supports Drug Repurposing Intelligence

Towards Healthcare Research & Consulting supports pharmaceutical companies, biotechnology developers, research organizations and investors through structured drug pipeline and competitive intelligence.

Relevant services include:

• Complete Master Datasets: Existing drug candidates, proposed new indications, company profiles, clinical stages and research activity.

• Competitive Quadrants: Benchmarking pharmaceutical and biotechnology companies based on pipeline maturity, therapeutic focus and development progress.

• Customized Dashboards: Tracking drug-disease relationships, clinical milestones, research partnerships and regulatory developments.

• Pipeline Intelligence: Monitoring existing molecules, new indication programmes, clinical studies and development changes.

• Buyer Identification: Identifying generic manufacturers, pharmaceutical developers, CROs, research institutions and potential licensing partners.

• GTM Strategy: Assessing therapeutic opportunities, development partnerships, geographic priorities and commercialization potential.

The Strategic Outlook

Drug repurposing is becoming an important area of pharmaceutical research as regulators and research organizations look for additional ways to address unmet medical needs.

The opportunity is not simply to find another use for an existing medicine. It is to identify drug-disease combinations with credible scientific evidence, a feasible development pathway and a sustainable commercial model.

For pharmaceutical leaders, biotechnology companies and investors, structured intelligence on existing molecules, clinical evidence and emerging partnerships can help identify opportunities that may otherwise remain overlooked.

Explore existing drug candidates, new therapeutic indications and pharmaceutical partnership opportunities with Towards Healthcare.